Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur Rev Med Pharmacol Sci ; 27(2): 501-510, 2023 01.
Artigo em Inglês | MEDLINE | ID: mdl-36734706

RESUMO

OBJECTIVE: Infection with Trichomonas vaginalis (TV) is the most prevalent non-viral sexually transmitted infection in the world. The objective of the study was to investigate the incidence of TV infection and its association with Human Papillomavirus (HPV) in a sample of Egyptian females. PATIENTS AND METHODS: 96 Egyptian females suspected for trichomoniasis were involved in our study. Vaginal washouts and cervical (cytobrush) samples were obtained from all patients and examined for T. vaginalis by direct wet mount, modified Diamond's culture medium, and real-time PCR. Cervical (cytobrush) samples were examined for HPV using real-time PCR. RESULTS: Out of 96 patients, 28 (29%) was positive for T. vaginalis by real-time PCR. HPV was detected in 33 patients (34.4%); 31 cases (32.3%) were infected with HPV of genotype 16, whereas only two cases (2.1%) had genotype 18 infection. A significant association was found between TV and HPV infection [Odds ratio (OR)=10.58; 95% confidence interval (CI): 3.819 - 29.29; p<0.001]. CONCLUSIONS: When it comes to diagnosing trichomoniasis in a susceptible population, real-time PCR is more reliable than traditional standard approaches. A significant association between TV and HPV infection was found. Further research into the processes by which these two organisms interact at the cellular level could be revealed.


Assuntos
Infecções por Papillomavirus , Tricomoníase , Vaginite por Trichomonas , Trichomonas vaginalis , Feminino , Humanos , Trichomonas vaginalis/genética , Vaginite por Trichomonas/diagnóstico , Vaginite por Trichomonas/epidemiologia , Vaginite por Trichomonas/complicações , Infecções por Papillomavirus/diagnóstico , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/complicações , Reação em Cadeia da Polimerase em Tempo Real , Papillomavirus Humano , Tricomoníase/complicações , Genótipo
2.
Artigo em Inglês | MEDLINE | ID: mdl-29780974

RESUMO

Metformin is the most widely administered anti-diabetic agent worldwide. In patients receiving metformin for metabolic syndrome or diabetes, it reduces the incidence and improves the survival of breast cancer (BC) patients. We have previously shown that metformin is particularly potent against triple negative breast cancer (TNBC), with a reduction of proliferation, oncogenicity and motility, inhibition of pro-oncogenic signaling pathways and induction of apoptosis. These BCs are well recognized to be highly dependent on glucose/glucosamine (metabolized through anaerobic glycolysis) and lipids, which are metabolized for the production of energy and cellular building blocks to sustain a high rate of proliferation. We have previously demonstrated that metformin inhibits lipid metabolism, specifically targeting fatty acid synthase (FASN), cholesterol biosynthesis and GM1 lipid rafts in TNBC. We also reported that glucose promotes phenotypic aggression and reduces metformin efficacy. We now show that metformin inhibits several key enzymes requisite to glucose metabolism in TNBC, providing additional insight into why metformin is especially toxic to this subtype of BC. Our data suggests that the use of metformin to target key metabolic defects in lipid and carbohydrate metabolism in cancer may be broadly applicable, especially against highly aggressive malignant cells.

3.
Contraception ; 32(3): 261-6, 1985 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-3936675

RESUMO

Ten breastfeeding women had the contraceptive implants NORPLANT inserted between days 30 and 39 postpartum. The immunoglobulins IgG, IgM and IgA were measured in the serum of the mothers and the infants before insertion and five months later. A control group of breastfeeding mothers who did not use any contraception or used local barrier methods were similarly studied. Although there were changes in the immunoglobulin levels with time in both mothers and infants, there were no group differences; this indicates that the use of NORPLANT does not influence these factors of humoral immunity.


PIP: This study measured major immunoglobulin levels in the serum of 10 breastfeeding mothers and their infants before insertion of the Norplant contraceptive implant (at 30-39 days postpartum) and again 5 months after insertion. 10 women who were also breastfeeding but either used no contraception or used barrier methods (diaphragm or condom) served as controls. Comparison of preinsertion and postinsertion mean serum concentrations revealed a significant rise in IgG and a significant decline in IgM in both groups of mothers. IgA concentrations declined after 6 months postpartum in both the study and control groups, but the difference was statistically significant only for women in the Norplant group. There were no significant differences between the 2 groups in changes occurring after 5 months. Similarly, there were no group differences, either at study admission or after 5 months, in the immunoglobulins of infants of Norplant-using women and controls. Overall, the changes in maternal and infant immunoglobulin levels noted in this study are similar to those expected during parturition and infancy. These results provide no evidence that use of hormonal contraception in the immediate postpartum period can make both mothers and infants more susceptible to infection. It is noted, however, that immunoglobulin levels are only 1 aspect of the immune system.


Assuntos
Aleitamento Materno , Anticoncepcionais Femininos/administração & dosagem , Imunoglobulinas/análise , Norgestrel/administração & dosagem , Período Pós-Parto , Adulto , Preparações de Ação Retardada , Feminino , Humanos , Imunoglobulina A/análise , Imunoglobulina G/análise , Imunoglobulina M/análise , Lactente , Recém-Nascido , Levanogestrel , Norgestrel/farmacologia , Gravidez
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...